Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume

Urology

Volumn 56, Issue 6, 2000, Pages 1011-1015

  Ahlegren, G ^a   Pedersen, K ^b   Lundberg, S ^b   Aus, G ^c   Hugosson, J ^c   Abrahamsson, P A ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b RYHOV COUNTY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CELL DIFFERENTIATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT FAILURE; TUMOR VOLUME;

CHROMOGRANIN A; CHROMOGRANINS; DISEASE-FREE SURVIVAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOADJUVANT THERAPY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033668744     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00838-4     Document Type: Article

References (14)

1. Peptide-hormone and serotonin-immunoreactive cells in normal and hyperplastic prostate glands
2. Neuroendocrine differentiation in prostatic carcinoma
3. Neuro-endocrine cells- a new prognostic parameter in prostate cancer
4. Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer?
5. Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy
6. The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long-term follow up study treated with radical prostatectomy
7. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma
8. The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neoadjuvant hormone treatment
9. Neuroendocrine differentiation in prostatic carcinoma
10. Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment
11. Correlation of pathologic findings with progression after radical retropubic prostatectomy
12. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy
13. Gleason grading of prostatic needle biopsies: Correlation with grade in 316 matched prostatectomies
14. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy